Photocure
The answer first
Does Photocure beat the market?
No, Photocure has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 26% of Nordic stocks
- Quality51
- Value51
- Trend16
No. 114 of 195 in healthcare
Expectations in the price
Moderate expectations
For the share to return about 9% a year from today's price, the cash Photocure keeps must grow about 6% a year for 10 years.
Max for seven days
Follow Photocure with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Photocure
Your first answer is free, no account needed.
Do you own Photocure, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Photocure and a few more. Free, no card.
Super Stock+44.6%In short
- Photocure has fallen 29.6% over the past year, including dividends.
- Overall, Photocure ranks better than 26% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 67.6%. The price is 72.4% below its peak now.
What do analysts think of Photocure?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 26% of Nordic stocks.
No. 114 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 128 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.19
- Asset turnoverSales divided by everything the company owns0.78
- Return on equityProfit divided by equity+8.3%
- Cash conversionOperating cash flow divided by profit1.70
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 50 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.9
- P/SPrice divided by sales1.6
- P/EPrice divided by earnings22.9
- P/CFPrice divided by operating cash flow13.5
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 139 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−22.9%
- 6 months−36.7%
- 9 months−33.4%
- 12 months−29.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Photocure
7 funds we follow own Photocure. The share is how much of the fund the stock makes up.
- Norway5
- Sweden2
- Lannebo Sverige PlusSweden · Lannebo1.0%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- Alfred Berg Indeks CNorway · Alfred Berg0.0%
- DNB Norge Indeks ANorway · DNB0.0%
- KLP AksjeNorge Indeks IINorway · KLP0.0%
- KLP AksjeNorge Indeks NNorway · KLP0.0%
- Storebrand Indeks Norge ANorway · Storebrand0.0%
From the funds' latest known holdings.
About Photocure
Photocure is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 99 employees.
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.


See the full analysis of Photocure.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card